Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS Q61K |
| Therapy | LY3214996 |
| Indication/Tumor Type | lung carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS Q61K | lung carcinoma | sensitive | LY3214996 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, patient-derived lung carcinoma cells harboring NRAS Q61K were sensitive to LY3214996 treatment in culture, and LY3214996 treatment led to reduction of tumor growth in a patient-derived xenograft (PDX) model (PMID: 33536188). | 33536188 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33536188) | ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer. | Full reference... |